CA
BCAX

CoreCap Advisors’s Bicara Therapeutics BCAX Stock Holding History

CoreCap Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$950 Hold
32
– – ﹤0.01% 2709
2026
Q1 		$636 Hold
32
– – ﹤0.01% 2613
2025
Q4 		$539 Hold
32
– – ﹤0.01% 2694
2025
Q3 		$505 Buy
+32
New +$358 ﹤0.01% 2567

Other funds holding BCAX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

CoreCap Advisors's BCAX Position: Q2 2026 in Review

CoreCap Advisors held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 32 shares worth $950. The position accounts for ﹤0.01% of the portfolio, ranked #2709.

CoreCap Advisors first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 5 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • CoreCap Advisors held 32 shares of Bicara Therapeutics worth $950 as of Q2 2026.
  • CoreCap Advisors left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2709 holding.
  • CoreCap Advisors first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 5 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.